Background: Frailty and medicine-related problems are common among the elderly and have been associated with an increased risk of adverse outcomes. However, there has been limited research on the association between frailty and medicines use. Aim: To determine the distribution of frailty among older people who used medicines and to examine the difference in frailty scores over time with continuation or discontinuation of specific medicines. Methods: The study population was from the Australian Longitudinal Study of Ageing (ALSA). The data used in the analysis were collected in 1992 (wave 1) and in 1995 (wave 3). Frailty scores were assessed at both waves using a modified version of the Frailty Index. Non-parametric tests were used to examine the difference in the distribution of frailty scores in relation to medicines used at baseline. Medicine use was categorised into continued or stopped by comparing use at wave 3 to use at baseline. A t-test was used to compare the mean changes in frailty scores between the two groups, with a p-value of <0.05 considered to be significant. Results: Data from 2087 participants were included. At baseline, a higher number of medicines used was associated with higher frailty scores (p < 0.0001). Stopping any preventive medicines, as well as beta-blockers, or potassium-sparing diuretics, was associated with a higher increase in mean frailty score changes than continuing these medicines, p = 0.01, p = 0.03 and p = 0.004, respectively. Conclusions: There was an association between frailty and medicines use. Further study is needed to assess whether the progression of frailty was due to medicine cessation or vice versa.
INTRODUCTION
Medicine-related problems are common in the older population and can lead to adverse health outcomes, such as hospitalisation and mortality. 1, 2 In 2011, the European Medicines Agency (EMA) identified the need to assess frailty as part of efforts to improve the safe use of medicines in older people 3 -as with medicines, frailty has also been associated with an increased risk of adverse health outcomes, including mortality, disability, nursing home admission, hospitalisations and falls. 4, 5 Frailty is 'a multidimensional syndrome characterized by decreased reserve and diminished resistance to stressors'. 6 A literature review identified that there are five dimensions of frailty: physical, psychological, medical, social and environmental. 7 Many of the adverse effects of medicines can be aligned with the dimensions of frailty. For example, medicine adverse effects that could affect the physical dimension of frailty include neuropathy, muscle weakness, sedation, confusion, dizziness, nausea, vomiting and diarrhoea. Similarly, the psychological dimension could be affected by medicine adverse effects such as depression or anxiety. Where an individual is being treated with medicines and suffering adverse effects that have the potential to affect dimensions assessed within the frailty measure, the medicines may be contributing to the assessment of being frail. Alternatively, the effects of medicine use could improve characteristics assessed in the frailty measures, which then may decrease the likelihood of being frail. For example, the use of paracetamol for pain management in osteoarthritis could help older individuals in maintaining their mobility as well as their independence in undertaking activities of daily living (ADL). Mobility and ADL are important characteristics often measured within the physical dimension of frailty. The use of antiemetics for nausea or antacids for indigestion could assist in preventing weight loss, which is another characteristic often measured within the physical dimension of frailty assessment.
Eight published studies have examined the association between medicine use and frailty in communitydwelling, older populations. [8] [9] [10] [11] [12] [13] [14] [15] The cross-sectional analysis from these studies showed that older people who were identified as frail were more likely to use analgesics 14 or to take inappropriate medicines as measured by the drug burden index, which includes sedative and anticholinergic medicines. 10, 15 The limitations of these studies included that the temporal associations between medicine use and frailty changes were not assessed. In addition, the association with frailty was only assessed for a limited range of medicines: analgesics, sedatives, anticholinergics, statins, anticoagulants and angiotensinconverting enzyme inhibitors (ACEIs). The effect of medicine use on the development of frailty over time has been examined in three longitudinal studies. [8] [9] [10] 15 The studies examined the incidence of frailty subsequent to use of preventive medicines, including statins 8 and ACEIs, 9 or high-risk prescribing as defined by use of multiple medicines (polypharmacy), and use of sedative or anticholinergic medicine. 10, 15 There was a similar incidence of frailty at the three-year follow up among users and non-users of statins (16% and 13%, p = 0.97), 8 and among users and non-users of ACEIs (20% and 14%, p = 0.88). 9 The study which examined the incidence of frailty with high-risk prescribing found that those with high-risk prescribing were more likely to develop frailty at the follow-up time. 10, 15 These studies were limited by the inclusion of the pre-frail as well as the non-frail in the initial cohorts, with the resultant issue being the inability to distinguish whether pre-frailty status or medicine use affected the outcome. The aim of this study was two-fold: first, to determine the distribution of frailty among older Australians who use medicines, including: potentially inappropriate medicines, symptom-relief medicines or preventive medicines. Second, to examine whether there was a difference in frailty scores over time with continuation or discontinuation of specific medicines. The study was conducted with the a priori hypotheses that the distribution of frailty score will be the same, regardless of the number or type of medicines used, and that older people who discontinued the use of potentially inappropriate medicines, symptom-relief medicines, or preventive medicines, would have no difference in frailty score changes over time.
METHODS

Study Population
The study used data from the Australian Longitudinal Study of Ageing (ALSA) which is a population-based cohort of 2087 participants aged 65 years and older. 16 Participants were recruited by random sampling from the South Australian electoral roll. The ALSA dataset contains information on the health and wellbeing of its participants; data collection was undertaken by interviews and clinical examinations. There were 13 waves of data collected. Medicine use data were collected in waves 1, 3, 6, 7, 9 and 11. Due to loss to follow up, some of the reasons of which were unknown, and the diminishing sample sizes in the later waves, this study used data from baseline (wave 1) which was collected in 1992 and data from the first follow-up period (wave 3) which was conducted between 1994-1995. Additional information can be found at http://www.flinders.edu.au/sabs/fcas/alsa/.
Frailty Assessment
Frailty assessment was conducted using a modified version of the Frailty Index (FI). 7 The modified FI included 20 variables (Appendix 1). The modified measure has been validated for both construct validity and predictive validity 7 and it has a comparable validity with the original FI 17 in this study population. While some authors argue that at least 30 items are needed for the FI, 18 quantitatively, as few as 20 items can be considered. In this study, the chronic disease variables were excluded from the FI. Frailty scores for each person were calculated by dividing the number of deficit variables present with the total number of deficits assessed for each person. The frailty score is a continuous score which ranges from 0 to 1, a greater score indicates increased frailty. Participants with more than 20% missing variables were excluded in the analysis. 19 A frailty score was calculated for each person at baseline and at wave 3.
Medicine Use Assessment
Medicine use was collected at both waves; a home interview was conducted where participants were asked to show the medicines containers, including for nonprescription medicines, and interviewers were instructed to write down information from the container labels where possible. 16 At the follow-up wave, the interviewer asked whether participants were still taking medicines from wave 1 as well as any new medicines taken after the last wave 1 interview. 16 The use of medicines was examined using cross-sectional and longitudinal analyses.
Results by specific medicines are reported for the top 25 most commonly used medicines at baseline (Figure 1 ). In the longitudinal analysis, the 25 medicines were categorised into: potentially inappropriate, symptom-relief and preventive medicines. Potentially inappropriate medicines include: non-steroidal anti-inflammatory drugs (NSAIDs), which are associated with risk of gastrointestinal bleeding, 20 benzodiazepines, which are associated with risk of falls and cognitive impairment, 20 digoxin, which is associated with risk of toxicity, 20 and opioids, which are associated with risk of hallucinations. 20 The
Australian Medicines Handbook (AMH) was used to classify symptom-relief medicines. 21 Five medicines were considered as falling within the symptom-relief category, including: antacids, paracetamol, histamine 2-antagonists, short-acting beta agonists (SABA) and stimulant laxatives. The other 14 medicines were considered as preventive medicines based on their rationale for use, which is to prevent disease complications. Medicine use was then categorised as continued or stopped, based on wave 3 data.
Statistical Analysis
Descriptive statistics were used to describe the baseline characteristics of the study population. Median FI scores for each group of medicine users at baseline and followup were examined. In the cross-sectional analysis, the non-parametric test (Wilcoxon rank sums test/KruskalWallis test) was used to examine if there was a difference in the distribution of frailty scores in relation to the number of medicines used.
In the longitudinal analysis, only participants who were alive at wave 3 were included. Chi-square tests and t-tests were used to compare the baseline Figure 1 Median and interquartile range (IQR) of frailty scores at baseline by medicine use. ICS = inhaled corticosteroid; H2 = histamine2; CCBs = calcium-channel blockers; ACEIs = angiotensin-converting enzyme inhibitors; K = potassium; NSAIDs = non-steroidal anti-inflammatory drugs; SABA = short-acting beta agonist. characteristics: gender, age, number of conditions and number of medicines between those who continued and those who stopped using medicine. The non-parametric test was used to compare the baseline median frailty score between those who continued and those who stopped using medicine. The mean changes in frailty scores were compared between the two groups using a t-test, with a p-value of <0.05 considered to be significant. For each individual, frailty score changes were calculated by subtracting the baseline frailty score from the frailty score at wave 3.
Adjustments for age, number of medicines, and comorbidities were not undertaken in this study because frailty is a condition that changes over time in a non-linear trend, with no consensus on the age at onset of frailty. 6 Comorbidities were also not adjusted as they have been shown to overlap with frailty status; but there is limited understanding of the causal relationship between comorbidity and frailty. 6 This results in a lack of clarity as to whether the overall number of medicines taken and the overall number of comorbidities a person has are true confounders or whether they are in the causal pathway. Adjusting for variables in the causal pathway can introduce bias toward the null. 22 For this reason, subgroup analysis was conducted when there was a significant difference in the baseline characteristics between those who continued and those who stopped using medicine. The analyses were undertaken using SAS version 9.4 for Windows (Copyright 2011, SAS Institute Inc., Cary, NC, USA).
RESULTS
Cross-sectional Analysis
A total of 2086 participants were included in the analysis. Table 1 shows the baseline characteristics of the ALSA population. Low-dose aspirin was the most common medicine used in the ALSA population with prevalence of 20.3%. The median baseline frailty score of participants by medicine used is shown in Figure 1 . Participants who reported use of statins had the lowest median frailty score, whereas those who reported use of opioids had the highest median frailty score.
There was a significant association between frailty and the number of medicines used (p < 0.0001) (Figure 2) . The frailty score increased with increasing numbers of medicines used.
Longitudinal Analysis
Baseline characteristics of those who continued and those who stopped using medicine were largely similar (Table 2) , with the exception of the number of medicines used. The groups who stopped using antacids and nitrates had a lower number of medicines at baseline compared to those who continued, while in SABA and thiazides users, those who stopped using the medicines had a statistically significant higher number of medicines at baseline than those who continued. The baseline frailty score in participants who stopped using statins was significantly higher than those who continued, with median scores of 0.138 and 0.063, respectively.
There were no statistically significant differences in the mean frailty score changes among participants who continued or stopped using potentially inappropriate medicines (PIMs) (Figure 3 ) or symptom-relief medicines ( Figure 4) . Participants who stopped at least one of 3 (1) (2) (3) (4) (5) the preventive medicines at wave 3 were found to have a higher increase in mean frailty score changes than those who continued using them (p = 0.01). For the individual preventive medicines, stopping beta blockers or potassium-sparing diuretics was associated with a greater increase in frailty score compared to continuing these medicines ( Figure 5 ).
DISCUSSION
Cross-sectional Analysis
This study was the first to examine the distribution of frailty scores across the total number of medicines used and by different types of medicines among a community-dwelling older population in Australia. The study showed that using greater numbers of medicines was associated with higher frailty scores. This result is consistent with a previous Australian study undertaken among older men that also showed that the greater the number of medicines used, the higher the frailty score.
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This study also showed that among participants who did not use medicines, their frailty score varied (Figure 2) , which suggests that frailty is not limited solely to the medical dimension, as some people on no medicines were assessed to be frail. This is in accord with the multidimensional definition of frailty which in addition to the medical dimension may also include physical, psychological, social and environmental dimensions. 6 The highest baseline median frailty score was found among opioid users, at 0.2, while the lowest median frailty score was among statins users, at 0.07. Half of the opioid users had a frailty score between 0.1 and 0.3, compared to 0.03 and 0.13 in statin users. The modified FI included daily activities functioning to assess frailty.
Opioids are used for pain management and pain has been associated with reduced physical function and performance, 23 which could affect daily activities functioning and may be a reason for the higher frailty score observed among opioid users. In terms of statin users, the findings may not reflect the current situation, as at the time of data collection in 1992, statins had been recently marketed, and therefore their use was limited. By comparison, in 2014, statins were among the most commonly dispensed medicines in Australia. 24 When considering medicines as preventive, symptomrelief or potentially inappropriate, the cross-sectional analysis shows that in general people on preventive medicines, such as antihypertensives had, lower frailty scores at baseline than people on symptom-relief medicines and potentially inappropriate medicines. In general, people on potentially inappropriate medicines had higher frailty scores at baseline.
Longitudinal Analysis
This study was the first to examine the differences in frailty changes between those who continued using medicines and those who stopped using medicines. There was no difference in the changes in frailty scores between those who stopped using potentially inappropriate medicines and those who continued using them. There was a non-statistically significant lower increase in the mean frailty score among those who stopped benzodiazepines and opioids, compared to those who continued. The small numbers of participants who stopped using benzodiazepines and opioids may have limited the power in this study. The use of benzodiazepines in older populations is not usually recommended due to their adverse effects. 20 A large prospective cohort study among 9360 community-dwelling older people who did not report impairment in mobility or ADL, found that the risk of developing mobility or ADL impairment among benzodiazepine users was higher than among non-users: hazard ratio (HR) 1.23, 95% confidence interval (CI), 1.09-1.39 for mobility impairment, and HR 1.28, 95% CI, 1.09-1.52 for ADL impairment. 25 Mobility and ADL impairment contribute to frailty development, therefore further research to better understand the effect of benzodiazepines on frailty development is required -without this knowledge, physicians may not link changes in frailty status or ADL with medicine use and thus preventive actions, such as ceasing the medicine, are unlikely to be implemented. This is particularly important considering that benzodiazepine use is common in Australia, with an Australian study using a general practitioner (GP) database finding that 16% (95% CI 11-21%) of patients aged 65 years or older used benzodiazepines. The results for the use of symptom-relief medicines showed there was no statistically significant difference in the change of frailty scores between those who stopped using symptom-relief medicines and those who continued using them. Symptom-relief medicines are often used intermittently and the extent of intermittent use at baseline compared to follow up could not be assessed in this study. Large differences in the extent of intermittent use across groups may have the potential to confound the result. In terms of preventive medicines, the results showed that those who continued using any preventive medicines had a lower increase in frailty scores than those who stopped using them. This was also found at the class level for beta-blockers and potassium-sparing diuretics. Moreover, there was a consistent pattern of non-statistically significant higher increases in frailty scores among participants who stopped taking preventive therapies (including low-dose aspirin, calcium channel blockers, frusemide, ACEIs, nitrates, thiazides and calcium supplements) compared to those who continued. While this could suggest that these medicines lessen the risk of developing frailty, it was not possible to determine the reason for the cessation of preventive therapies. It is possible that worsening frailty led to discontinuation of preventive medicines rather than the use of preventive medicines preventing the development of frailty. The higher increase in frailty scores among participants who discontinued using preventive medicines may be due to several reasons, including the development of side effects which may lead to the need to discontinue the medicine and limit the participant benefiting from the medicine. Another reason is the worsening of health conditions, or the development of new conditions, all of which may in turn contribute to increasing frailty and may require discontinuation of certain medicines, particularly where there may be contraindications to their use. Additionally, among people who were approaching the end of life, preventive medicine may be proactively ceased as the person has insufficient life expectancy to benefit from preventive therapies.
A larger study with sufficient power may confirm whether the use of preventive medicines may be beneficial in reducing frailty development in the older population. Additionally, the study would need to include assessment of the doctor's reason for cessation and frailty assessment at the time of cessation, to provide further insight as to whether ceasing preventive therapy increases the risk of frailty or whether worsening frailty was a factor contributing to the doctor's decision to cease the medicine.
Strengths and Limitations of the Study
This study is the first study to examine the association between medicine use and frailty over time in a community-dwelling older population using a multidimensional frailty measure. Previous studies have used unidimensional measures [8] [9] [10] 15 or have been limited to populations of older men 10, 15 or older women. 8, 9 To the best of our knowledge this study was also the first study to consider how cessation of medicine use may affect changes in frailty scores over time.
One of the limitations of this study was that the data were collected between 1992 and 1995; this limitation is particularly evident when considering the utilisation of statins. Statins were introduced in the early 1990s, 27 and the low prevalence of the use of statins in our study population, at 2.9%, is markedly different from the current prevalence of use among older Australian aged 64-74 years, which is estimated to be at over 40%. 28 However, the majority of medicines examined in this study, including low-dose aspirin, thiazides, beta blockers, paracetamol and NSAIDs, are still among the most common medicines used among older Australians. 28 The analysis on the medicine use and frailty changes was conducted only among participants who were alive at the follow-up wave, therefore the results may have survivorship bias. Another limitation of this study is that information on the time of medicine discontinuation was not available, nor was information available to ascertain the duration of medicine discontinuation prior to the frailty assessment at follow-up. Additionally, there was no information on the reasons for either continuation or discontinuation of medicines. Therefore, it was not possible to assess whether frailty changes were due to medicines cessation or whether medicine use changes were due to frailty progression. Further study which utilises data that offer the ability to measure frailty at the time of medicine discontinuation, as well as the availability of comprehensive information on the reason for discontinuation, is necessary to understand the association between frailty and medicine use.
CONCLUSION
This study found there was a significant positive association between frailty score and the number of medicines used at baseline. Of the 25 medicines examined, opioid users at baseline had the highest median frailty score, at 0.2, while statins users had the lowest median frailty score, at 0.07.
During the three-year follow up period, there was an increase in the mean frailty scores in all medicine user groups examined. This study found no difference in frailty scores among participants who continued and discontinued the use of potentially inappropriate medicines. In terms of preventive medicines, participants who stopped using any preventive medicines had a greater increase in mean frailty score than those who continued using the medicine. However, further study that includes assessment of frailty at the time of discontinuation as well as examination of the reasons for either continuation or discontinuation of medicines is warranted to determine if frailty changes were due to medicine use changes or vice versa.
APPENDIX 1
The modified Frailty Index 
